Theragen EtexLtd Past Earnings Performance
Past criteria checks 4/6
Theragen EtexLtd has been growing earnings at an average annual rate of 0.1%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 11.9% per year. Theragen EtexLtd's return on equity is 19.6%, and it has net margins of 12.5%.
Key information
0.1%
Earnings growth rate
-0.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 11.9% |
| Return on equity | 19.6% |
| Net Margin | 12.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Theragen EtexLtd's (KOSDAQ:066700) Solid Profits Have Weak Fundamentals
Mar 27
We're Not So Sure You Should Rely on Theragen EtexLtd's (KOSDAQ:066700) Statutory Earnings
Nov 23Recent updates
Theragen EtexLtd's (KOSDAQ:066700) Solid Profits Have Weak Fundamentals
Mar 27Calculating The Intrinsic Value Of Theragen Etex Co.,Ltd. (KOSDAQ:066700)
Mar 21Is Theragen EtexLtd (KOSDAQ:066700) A Risky Investment?
Feb 11
Did Theragen EtexLtd's (KOSDAQ:066700) Share Price Deserve to Gain 36%?
Jan 16A Look At The Intrinsic Value Of Theragen Etex Co.,Ltd. (KOSDAQ:066700)
Dec 21We're Not So Sure You Should Rely on Theragen EtexLtd's (KOSDAQ:066700) Statutory Earnings
Nov 23Revenue & Expenses BreakdownBeta
How Theragen EtexLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 221,725 | 27,774 | 83,123 | 4,672 |
| 30 Sep 23 | 212,214 | 3,341 | 80,315 | 5,125 |
| 30 Jun 23 | 204,469 | 4,120 | 71,724 | 4,767 |
| 31 Mar 23 | 196,593 | 5,771 | 64,683 | 5,097 |
| 31 Dec 22 | 190,769 | 11,038 | 58,266 | 5,038 |
| 30 Sep 22 | 186,888 | 7,854 | 60,569 | 5,133 |
| 30 Jun 22 | 181,746 | -1,429 | 63,492 | 5,656 |
| 31 Mar 22 | 176,380 | -5,700 | 63,753 | 5,986 |
| 31 Dec 21 | 166,567 | -11,854 | 60,251 | 6,515 |
| 30 Sep 21 | 158,350 | -9,012 | 55,442 | 6,867 |
| 30 Jun 21 | 154,033 | -5,947 | 52,606 | 7,072 |
| 31 Mar 21 | 147,518 | -9,595 | 49,588 | 6,797 |
| 31 Dec 20 | 143,023 | -8,968 | 44,909 | 6,418 |
| 30 Sep 20 | 141,701 | 33,345 | 36,404 | 5,628 |
| 30 Jun 20 | 137,216 | 34,496 | 32,032 | 4,732 |
| 31 Mar 20 | 140,553 | 44,760 | 29,115 | 4,340 |
| 31 Dec 19 | 138,083 | 43,646 | 28,848 | 4,099 |
| 30 Sep 19 | 137,076 | -3,218 | 28,535 | 4,157 |
| 30 Jun 19 | 133,374 | -6,198 | 27,878 | 4,345 |
| 31 Mar 19 | 121,750 | -10,334 | 27,821 | 4,207 |
| 31 Dec 18 | 117,475 | -10,218 | 27,794 | 4,171 |
| 30 Sep 18 | 112,293 | -488 | 26,503 | 5,098 |
| 30 Jun 18 | 108,914 | 1,650 | 27,314 | 4,543 |
| 31 Mar 18 | 110,585 | 743 | 28,187 | 3,545 |
| 31 Dec 17 | 107,592 | 1,274 | 28,288 | 3,366 |
| 30 Sep 17 | 107,268 | -1,617 | 29,704 | 2,506 |
| 30 Jun 17 | 103,572 | -154 | 28,352 | 2,838 |
| 31 Mar 17 | 99,384 | 534 | 26,163 | 3,806 |
| 31 Dec 16 | 101,283 | 2,043 | 25,228 | 3,944 |
| 30 Sep 16 | 97,942 | -6,495 | 27,172 | 4,087 |
| 30 Jun 16 | 99,460 | -6,824 | 29,038 | 3,768 |
| 31 Mar 16 | 100,873 | -6,550 | 30,467 | 3,702 |
| 31 Dec 15 | 98,884 | -6,803 | 31,524 | 3,632 |
| 30 Sep 15 | 90,006 | 3,665 | 26,570 | 3,231 |
| 30 Jun 15 | 87,810 | 3,975 | 25,917 | 3,350 |
| 31 Mar 15 | 86,831 | 1,932 | 26,544 | 3,070 |
| 31 Dec 14 | 89,743 | 1,479 | 26,798 | 3,079 |
| 30 Sep 14 | 98,082 | 723 | 28,307 | 3,834 |
| 30 Jun 14 | 96,558 | -421 | 26,790 | 3,827 |
| 31 Mar 14 | 96,706 | 1,208 | 25,111 | 4,101 |
| 31 Dec 13 | 90,731 | 1,327 | 23,346 | 4,210 |
| 30 Sep 13 | 78,662 | -3,184 | 24,012 | 3,392 |
| 30 Jun 13 | 85,137 | -4,104 | 24,520 | 3,855 |
Quality Earnings: A066700 has a large one-off gain of ₩22.5B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: A066700's current net profit margins (12.5%) are higher than last year (5.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A066700 has become profitable over the past 5 years, growing earnings by 0.1% per year.
Accelerating Growth: A066700's earnings growth over the past year (151.6%) exceeds its 5-year average (0.1% per year).
Earnings vs Industry: A066700 earnings growth over the past year (151.6%) exceeded the Pharmaceuticals industry 34.6%.
Return on Equity
High ROE: A066700's Return on Equity (19.6%) is considered low.